Primärquellen-Eintrag
EntscheidungsrelevantTopline-Ergebnisse
Daré Bioscience: positive Zwischenergebnisse der Phase-3-Studie zu Ovaprene
Interim Phase 3 data from 339 subjects (1,789 cycles) show ~9% pregnancy rate, consistent with prior expectations. DSMB recommends study continue without modification; no new safety signals emerged and discontinuation due to vaginal odor fell 5% versus July 2025 review.
Kernfakten
- Eingereicht
- 12. Mai 2026, 12:00
- Ereignis
- Topline-Ergebnisse
- Richtung
- Positiv
- Unternehmen
DAREDare Bioscience, Inc.- Asset
- Flora Sync LF5
- Quelle
- Unternehmensmitteilung
- Belegstatus
- Belegt
- Zielzyklen
- 2.500
- Schwangerschaftsrate
- etwa 9 %
- Ausgewertete Zyklen
- 1.789
- Abbruchrate
- 12 %
- Abbruchabnahme
- 5 %
Auszug aus der Quelle
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive Second Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovaprene’s Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness, safety and acceptability of Ovaprene®, the company’s investigational monthly, hormone-free intravaginal contraceptive. There currently
Mehr zu diesem Asset
Beachtenswert
13. Aug. 2026
20:02
DAREDare Bioscience, Inc.Daré Bioscience meldet Q2 2026 Ergebnisse und startet Flora Sync LF5
Entscheidungsrelevant
14. Mai 2026
20:01
DAREDare Bioscience, Inc.